# DBV Technologies (DBVT) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/DBVT
## Company Profile
- Ticker: DBVT
- Exchange: NASDAQ
- Sector: Biopharma
- Location: France
- Tags: Immunotherapy
## Stock Data
- Close: 13.27 USD
- Market cap: 1078969092.88 USD
- Last updated: 2026-09-08
## Business Overview
DBV Technologies is a food-allergy company focused on epicutaneous immunotherapy and allergic disease. Its platform aims to use skin-based delivery to modulate immune response.
## Why The Stock Is Moving

As of Sep 8, 2026, DBVT closed down 1.48% at $13.27. No new same-company headline was identified in the current news window.

## Geographic Base

Headquartered in France and listed on NASDAQ as an ADR, DBV has a global allergy-biotech profile.

## Business Model

The business depends on clinical data, regulatory progress, and the potential to turn immunotherapy for allergies into a commercial story.

## Landscape Position

DBV is a niche allergy biotech whose stock is highly sensitive to regulatory and clinical updates.

## Future Catalysts

- DBV’s catalysts are Viaskin Peanut and any FDA or clinical step that keeps the food-allergy franchise alive. The next regulatory update matters because the company has spent years trying to bring the patch platform across the finish line.

## Recent News
- 2016-07-05 05:34 EST — [DBV Technologies Proudly Welcomes Dr. Lucia Septien as Chief Medical Officer](https://biopharmsignal.com/news/DBVT/dbv-technologies-proudly-welcomes-dr-lucia-septien-as-chief-medical-officer-98a84dd7) — Source: DBV Technologies
- 2016-06-21 20:32 EST — [DBV Technologies Expands its Board of Directors with the Appointments of Claire Giraut and Mailys Ferrere](https://biopharmsignal.com/news/DBVT/dbv-technologies-expands-its-board-of-directors-with-the-appointments-of-claire--e6340e8b) — Source: DBV Technologies
- 2016-06-15 20:34 EST — [DBV Technologies: Late-Breaking Presentation at EAACI Highlights Viaskin(r) Peanut Data Providing Biomarker Insights for Monitoring Treatment Progression](https://biopharmsignal.com/news/DBVT/dbv-technologies-late-breaking-presentation-at-eaaci-highlights-viaskin-r-peanut-f16d0c47) — Source: DBV Technologies
- 2016-06-13 05:36 EST — [DBV Technologies Announces Publication of Preclinical Data in JACI Suggesting EPIT(r) Provides Sustained Protection Against Anaphylaxis](https://biopharmsignal.com/news/DBVT/dbv-technologies-announces-publication-of-preclinical-data-in-jaci-suggesting-ep-0ad571fe) — Source: DBV Technologies
- 2016-05-31 05:06 EST — [DBV Technologies and Nestle Health Science Form Collaboration to Develop and Commercialize a Novel Diagnostic Test for Pediatric Milk Allergy](https://biopharmsignal.com/news/DBVT/dbv-technologies-and-nestle-health-science-form-collaboration-to-develop-and-com-57247f48) — Source: DBV Technologies